IMHO an equivalent ASX listed product / businesses include AVH & NAN;
AVH: Annual revenue = 100m, NP = 10m, Market cap = $2.13 Billion
NAN: Annual revenue run rate = 20 m, NP = nil, Market Cap = $778 million
GSS: Annual Revene run rate = 37m, NP = 10m whilst sustaining costs associated with growth of 500% P.A. plus, Market Cap = $283 million
Due to the net profit parity - albeit with faster growth & a larger addressable market, IMHO price target for the market cap is value parity with NAN $2.83 billion, circa $20 per share conservatively if growth slows to normal within 5 years, if growth continues at the current rate & due to the boost from relationships formed it could be much much earlier.
Hopefully the co - targets reimbursement lobbying for superior products across EU / ANZ as a priority, options and share incentives for high performing well connected health sales team or contractors and in fact blows my target price out of the water
- Forums
- ASX - By Stock
- GSS
- Ann: CE-IVD received for STI test
Ann: CE-IVD received for STI test, page-6
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GSS (ASX) to my watchlist
(20min delay)
|
|||||
Last
72.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $164.4M |
Open | High | Low | Value | Volume |
72.0¢ | 72.5¢ | 72.0¢ | $5.802K | 8.003K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 17989 | 70.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
73.0¢ | 2149 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 17989 | 0.705 |
3 | 7463 | 0.700 |
1 | 15000 | 0.690 |
2 | 10880 | 0.680 |
1 | 100000 | 0.650 |
Price($) | Vol. | No. |
---|---|---|
0.730 | 2149 | 2 |
0.745 | 3595 | 1 |
0.750 | 22017 | 2 |
0.760 | 39008 | 2 |
0.800 | 500 | 1 |
Last trade - 14.19pm 10/09/2024 (20 minute delay) ? |
Featured News
GSS (ASX) Chart |